IL‐6 as an intracrine growth factor for renal carcinoma cell lines

No abstract is available for this paper.

• Publication year

  2004

• Venue

  International Journal of Cancer

• Publication date

  2004-09-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.20287PMID 15252833
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• C/EBP homologous protein (CHOP) up‐regulates IL‐6 transcription by trapping negative regulating NF‐IL6 isoform

  2003cited by this paper
• Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.

  2003cited by this paper
• Intracellular IL-1Ra type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-kappaB pathways.

  2003cited by this paper
• In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.

  2002cited by this paper
• Expression of Interleukin 13 Receptor in Glioma and Renal Cell Carcinoma: IL13Rα2 as a Decoy Receptor for IL13

  2001cited by this paper
• STAT3 is constitutively activated in Hodgkin cell lines.

  2001cited by this paper
• The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study

  2000cited by this paper
• Are renal cell carcinoma cells able to modulate the cytotoxic effect of tumor infiltrating lymphocytes by secretion of interleukin-6?

  1999cited by this paper
• Inhibition of interleukin-6 promoter activity by the 24 kDa isoform of fibroblast growth factor-2 in HeLa cells.

  1999cited by this paper
• Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

  1998cited by this paper
• Overexpression of the FGF‐2 24‐kDa isoform up‐regulates IL‐6 transcription in NIH‐3T3 cells

  1998cited by this paper
• Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

  1998cited by this paper
• Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor.

  1998cited by this paper
• Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma.

  1997cited by this paper
• The family of the IL‐6‐Type cytokines: Specificity and promiscuity of the receptor complexes

  1997cited by this paper
• IL-6 is a survival prognostic factor in renal cell carcinoma.

  1997cited by this paper
• Role of interleukin‐6 in the paraneoplastic inflammatory syndrome associated with renal‐cell carcinoma

  1997cited by this paper
• Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?

  1997cited by this paper
• Expression of the interleukin 6 receptor in primary renal cell carcinoma.

  1997cited by this paper
• Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain.

  1996cited by this paper
• T helper 2 cytokines differently regulate monocyte chemoattractant protein-1 production by human peripheral blood monocytes and alveolar macrophages.

  1996cited by this paper
• Interleukin 13 inhibits macrophage inflammatory protein-1 alpha production from human alveolar macrophages and monocytes.

  1996cited by this paper
• A Di-leucine Motif and an Upstream Serine in the Interleukin-6 (IL-6) Signal Transducer gp130 Mediate Ligand-induced Endocytosis and Down-regulation of the IL-6 Receptor (*)

  1996cited by this paper
• Interleukin-13 (IL-13) induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein.

  1996cited by this paper
• IL-6 antisense-mediated growth inhibition of a choriocarcinoma cell line: an intracellular autocrine growth mechanism.

  1996cited by this paper
• Detection and analysis of an alternatively spliced isoform of interleukin-6 mRNA in peripheral blood mononuclear cells.

  1995cited by this paper
• Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.

  1995cited by this paper
• Regulatory effects of IL‐13 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis

  1995cited by this paper
• IL-13 down-regulates CD14 expression and TNF-alpha secretion in normal human monocytes.

  1995cited by this paper
• Contrasting effect of interleukin-13 on interleukin-1 receptor antagonist and proinflammatory cytokine production by human alveolar macrophages.

  1995cited by this paper
• Local production of interleukin 6 by renal adenocarcinoma in vivo.

  1994cited by this paper
• Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells.

  1994cited by this paper
• Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma.

  1994cited by this paper
• Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma.

  1994cited by this paper
• Expression of high‐affinity IL‐4 receptors on human melanoma, ovarian and breast carcinoma cells

  1994cited by this paper
• Tumour necrosis factor-α, interleukin-1β and interleukin-6 in patients with renal cell carcinoma

  1994cited by this paper
• Interleukin-13 inhibits the proliferation of normal and leukemic human B-cell precursors.

  1994cited by this paper
• Human interleukin‐13 activates the interleukin‐4‐dependent transcription factor NF‐IL4 sharing a DNA binding motif with an interferon‐γ‐induced nuclear binding factor

  1994cited by this paper
• Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

  1993cited by this paper
• Role of interleukin-6 in paraneoplastic thrombocytosis [letter]

  1993cited by this paper
• Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses.

  1993cited by this paper
• Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4.

  1993cited by this paper
• Molecular cloning of the MCP-3 chemokine gene and regulation of its expression.

  1993cited by this paper
• Modulation of murine macrophage function by IL-13.

  1993cited by this paper
• Further study of internal autocrine regulation of multipotent hematopoietic cells.

  1993cited by this paper
• Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

  1992cited by this paper
• Inhibition of colon and breast carcinoma cell growth by interleukin-4.

  1992cited by this paper
• The hepatic interleukin‐6 receptor Down‐regulation of the interleukin‐6 binding subunit (gp80) by its ligand

  1992cited by this paper
• Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins.

  1992cited by this paper
• Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor.

  1991cited by this paper
• Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines.

  1991cited by this paper
• AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.

  1990cited by this paper
• Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas

  1989cited by this paper
• Functional interactions of IL2 and TNF in the differentiation of LGL into lak effectors

  1989cited by this paper
• Autocrine stimulation of intracellular PDGF receptors in v-sis-transformed cells.

  1988cited by this paper
• Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

  1988cited by this paper
• Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney

  1986cited by this paper

• New insights in cellular senescence: The pituitary model

  2025influential citation
• The role of cytokines in shaping the future of Cancer immunotherapy.

  2025cites this paper
• IL-6 significantly correlated with the prognosis in low-grade glioma and the mediating effect of immune microenvironment

  2024cites this paper
• Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors

  2023cites this paper
• Large-scale analysis of cell-cell communication reveals angiogenin-dependent tumor progression in clear cell renal cell carcinoma

  2023cites this paper
• A compendium of validated pain genes

  2022cites this paper
• IL6 and CCL18 Mediate Cross-talk between VHL-Deficient Kidney Cells and Macrophages during Development of Renal Cell Carcinoma

  2022cites this paper
• Plasmodium-encoded murine IL-6 impairs liver stage infection and elicits long-lasting sterilizing immunity

  2021cites this paper
• On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma

  2021cites this paper
• Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma

  2021cites this paper
• Development and validation of a PBRM1‐associated immune prognostic model for clear cell renal cell carcinoma

  2021cites this paper
• Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma

  2020cites this paper
• Identification of an immune-related risk signature for predicting prognosis in clear cell renal cell carcinoma

  2020cites this paper
• Intracellular role of IL-6 in mesenchymal stromal cell immunosuppression and proliferation

  2020cites this paper
• Anti-tumour effect of tocilizumab for osteosarcoma cell lines

  2020cites this paper
• Regulatory T-Cells and Th17 Cells in Tumor Microenvironment

  2020cites this paper
• Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis

  2019cites this paper
• CMAR_A_208839 6163..6173

  2019influential citation
• Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis

  2019cites this paper
• G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas

  2018cites this paper
• IL1 genes polymorphism and the risk of renal cell carcinoma in Chinese Han population

  2017cites this paper
• Analysis of aqueous humor concentrations of cytokines in retinoblastoma

  2017cites this paper
• Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy

  2017cites this paper
• Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors.

  2017cites this paper
• Gr upSM Interleukin-6 as a Therapeutic Target on Human Cancer

  2017cites this paper
• Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b.

  2017cites this paper
• Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma

  2016cites this paper
• Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance.

  2016cites this paper
• Age-Related Macular Degeneration and Intracrine Biology: An Hypothesis.

  2016cites this paper
• A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

  2015cites this paper
• Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.

  2015cites this paper
• Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis

  2015cites this paper
• Interleukin-6 as an emerging regulator of renal cell cancer.

  2015cites this paper
• Interleukin-6 as a Therapeutic Target

  2015influential citation
• The nucleocrine pathway comes of age.

  2015influential citation
• Regulatory T Cells and Th17 Cells in Cancer Microenvironment

  2015cites this paper
• [Not Available].

  2015cites this paper
• Identification des voies de signalisations essentielles à la progression tumorale dans les sarcomes : un modèle pour les interactions cellules tumorales et stroma

  2015cites this paper
• Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

  2015cites this paper
• IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis

  2014cites this paper
• Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.

  2014cites this paper
• IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.

  2014cites this paper
• Profiles of circulating endothelial cells and serum cytokines during adjuvant chemoradiation in rectal cancer patients

  2013cites this paper
• Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas

  2013cites this paper
• The Key Role of IL-6–Arginase Cascade for Inducing Dendritic Cell–Dependent CD4+ T Cell Dysfunction in Tumor-Bearing Mice

  2013cites this paper
• Protease-activated receptor 2 signaling upregulates angiogenic growth factors in renal cell carcinoma.

  2013cites this paper
• Cell Dysfunction in Tumor-Bearing Mice Dependent CD4+ T - Inducing Dendritic Cell Arginase Cascade for - The Key Role of IL-6

  2013cites this paper
• Evidence for IL-12 intracrine activity in DC

  2012cites this paper
• Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.

  2012cites this paper
• AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications

  2012cites this paper
• Depressive Symptoms and Cortisol Rhythmicity Predict Survival in Patients with Renal Cell Carcinoma: Role of Inflammatory Signaling

  2012cites this paper
• Mutations of the von Hippel–Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma

  2011cites this paper
• Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma.

  2011cites this paper
• Hepassocin regulates cell proliferation of the human hepatic cells L02 and hepatocarcinoma cells through different mechanisms

  2011cites this paper
• IL-6 antisense-mediated growth inhibition in a head and neck squamous cell carcinoma cell line.

  2011cites this paper
• Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer?

  2011cites this paper
• Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation.

  2010cites this paper
• Lack of Knowledge: Breast Cancer and the Soluble Interleukin-6 Receptor

  2010cites this paper
• Controlled Growth Factor Delivery for Tissue Engineering

  2009cites this paper
• Senescence, apoptosis, and stem cell biology: the rationale for an expanded view of intracrine action.

  2009cites this paper
• Proteasom-Inhibition überwindet die Resistenz von Nierenzellkarzinom-Zelllinien gegenüber PPARgamma-Aktivierung

  2009cites this paper
• Lymphoma and Myeloma Cell Resistance to Cytotoxic Agents and Ionizing Radiations Is Not Affected by Exposure to Anti–IL-6 Antibody

  2009cites this paper
• Prognostic factors and selection for clinical studies of patients with kidney cancer.

  2008cites this paper
• Tumor-induced modulation of dendritic cell function.

  2008cites this paper
• Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma.

  2008cites this paper
• [Interleukin-6 and epithelial tumours: new convincing arguments in favour of the use of IL-6 targeted therapies].

  2008cites this paper
• Tocilizumab for the treatment of rheumatoid arthritis

  2008cites this paper
• The Growth-Inhibitory Effects of Dexamethasone on Renal Cell Carcinoma In Vivo and In Vitro

  2008cites this paper
• Characterization of Primary Renal Carcinoma Cultures

  2007cites this paper
• Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor.

  2007cites this paper
• Interleukin-4 Promoter Polymorphisms: A Genetic Prognostic Factor for Survival in Metastatic Renal Cell Carcinoma

  2007cites this paper
• Regulation of IL-6 signal transduction, contributions of the Signal Regulatory Protein (SIRP) and cyclic AMP

  2007cites this paper
• Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?

  2006cites this paper
• Interleukin‐6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte–dendritic cell cross‐talk

  2006cites this paper
• The intracrine hypothesis: an update.

  2006cites this paper
• IL-4 inhibits the TNF-α induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-α to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses

  2006influential citation
• Significance of Autologous Interleukin‐6 Production in the HA22T/VGH Cell Model of Hepatocellular Carcinoma

  2006cites this paper
• Overexpression of Tumor Necrosis Factor Alpha by a Recombinant Rabies Virus Attenuates Replication in Neurons and Prevents Lethal Infection in Mice

  2005cites this paper
• Renal cell cancers prognostic factors (nomograms) Related review: Predicting outcomes in renal cell carcinoma (pp. 289–297)

  2005cites this paper
• Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes

  2005cites this paper
• A spliced isoform of interleukin 6 mRNA produced by renal cell carcinoma encodes for an interleukin 6 inhibitor.

  2005cites this paper
• Head and Neck

  2005cites this paper